Our latest articles
UCB makes a rare acquisition
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
Cytokinetics hopes to resurrect omecamtiv
Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
Device makers buy big
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
Biotech investors pray for a takeover miracle
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
Proqr eyes its first big test
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
Biogen hints at jobs cuts unless government pays up
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
After a record year, where next for biopharma flotations?
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
JP Morgan 2022 – Abbvie looks to crack the cystic fibrosis code
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.
Aduhelm verdict puts the heat on Biogen – and on the FDA
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
